Canada Pet Veterinary Diet - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The canada pet veterinary diet market size is USD 746.12 million in 2025, projected to reach USD 784.55 million in 2026, and further anticipated to reach USD 1.12 billion by 2031, growing at a CAGR of 7.53% during the forecast period (2026 to 2031). This report is Segmented by Product Type (Diabetes, Digestive Sensitivity, Oral Care Diet, Renal, Urinary Tract Disease, Derma, and More), by Pets (Dogs, Cats, and Other Pets), and by Distribution Channel (Online Channel, Specialty Stores, Supermarkets and Hypermarkets, Convenience Stores, and Other Channels). The Market Forecasts are Provided in Terms of Value (USD) and Volume (Metric Tons).

Canada Pet Veterinary Diet Market Trends and Insights

Rising Diagnosis Rates for Chronic Pet Conditions

Higher diagnosis rates for chronic conditions in dogs and cats are supporting growth in the Canada pet veterinary diet market. The high prevalence of health conditions among companion animals continues to require condition-specific nutrition. This trend is significant because therapeutic diets are often used as part of ongoing disease management rather than short-term support. According to a 2025 study published in the Journal of Veterinary Internal Medicine, repeated health screening and routine clinical monitoring facilitate earlier detection of chronic diseases in aging companion animals, enabling earlier clinical intervention and potentially extending the duration over which therapeutic nutritional management can be implemented. As a result, the market is benefiting from both broader diagnosis rates and longer durations of nutritional intervention.

Expansion of Veterinary-Linked Prescription Commerce

The market is supported by prescription commerce that remains closely tied to veterinary care. Once a veterinarian recommends a specific formula and the pet owner begins purchasing it through an authorized channel, refill patterns tend to stabilize, as product substitution is less common in clinically managed feeding routines. This creates a demand structure that is more predictable than general premium pet food and more resistant to switching. This framework is now extending into digital refill pathways, as prescription-linked nutrition claims and authorization processes remain within the professional care channel even when product fulfillment moves online.

Premium Pricing Limits Mass-Market Penetration

The Canada pet veterinary diet market faces an affordability constraint, as therapeutic formulas are priced at a clear premium over standard pet food. This is most apparent in households managing multiple pets or multiple conditions simultaneously, where cumulative feeding costs can become difficult to sustain. The pricing challenge is more pronounced in categories that require prolonged feeding rather than short-term nutritional intervention. This creates a practical ceiling on household penetration even when the clinical need for the product is evident. The result is a gap between medical relevance and the number of owners who can maintain long-term adherence.

Other drivers and restraints analyzed in the detailed report include:

• Humanization of Pet Health Spending
• Tele-Veterinary Follow-Up and Digital Refill Adoption
• Prescription Dependency Slows Impulse Purchase Conversion

Segment Analysis

Digestive sensitivity held 16.9% of the Canada pet veterinary diet market in 2025, making it the largest product group in the market. Digestive formulas held this position because gastrointestinal conditions are common across both dogs and cats and often require prolonged dietary management once diagnosed. This gives the segment a broader and steadier refill base than narrower therapeutic categories tied to fewer clinical indications. The category also benefits from stronger clinical acceptance because digestive outcomes are visible to owners and easier to monitor through day-to-day changes in stool quality, appetite, and tolerance. A 2025 randomized controlled trial published in Frontiers in Veterinary Science showed that a prescription diet containing Bacillus velezensis DSM 15544, fructo-oligosaccharides, plasma immunoglobulin, yeast, and sepiolite reduced the time to normalization of fecal consistency in dogs with acute diarrhea.

Oral care diets are projected to grow at a 8.2% CAGR between 2026 and 2031, making it the fastest-growing category in the market. Oral care diets are growing faster because dental disease is common in companion animals, and nutritional management has seen lower conversion rates to therapeutic diets than renal or gastrointestinal care. Periodontal disease is the most common clinical condition in companion animals, leaving a large addressable base for diet-led oral care intervention as veterinary recommendations increase. Renal and urinary tract disease diets remain a strong mid-tier category because feline kidney disease and urinary condition management are closely linked to long-duration feeding protocols, while obesity, dermatology, and diabetes formulas are gaining traction as brands introduce more targeted and multi-condition products to market.

Complete Report Scope:

• By Product Type
  • Diabetes
  • Renal
  • Urinary Tract Disease
  • Digestive Sensitivity
  • Oral Care Diet
  • Derma Diet
  • Obesity Diet
  • Other Veterinary Diet
• By Pet Type
  • Dogs
  • Cats
  • Other Pets
• By Distribution Channel
  • Convenience Stores
  • Online Channel
  • Specialty Stores
  • Supermarkets and Hypermarkets
  • Other Channels

List of Companies Covered in this Report:

• Mars, Incorporated (Royal Canin)
• Nestlé S.A. (Nestlé Purina PetCare)
• Colgate-Palmolive Company (Hill's Pet Nutrition)
• General Mills, Inc. (Blue Buffalo Pet Products, Inc.)
• Schell and Kampeter, Inc. (Diamond Pet Foods)
• Farmina Pet Foods Holding (Farmina Pet Foods)
• PLB International Inc. (PLB International)
• Vetdiet Inc. (Vetdiet)
• Virbac S.A. (Virbac)
• Dechra Pharmaceuticals Limited (Dechra)
• Elanco Animal Health Incorporated (Elanco)
• Vetoquinol S.A. (Vetoquinol)
• Petcurean Pet Nutrition Inc. (Petcurean)
• Kemin Industries, Inc. (Kemin)
• Alltech, Inc. (Alltech)
• Nutrience (Elmira Pet Products Ltd.)
• Hagen Group (Rolf C. Hagen Inc.)
• Rayne Clinical Nutrition LLC (Rayne Clinical Nutrition)

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support